Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 1(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05867420Phase 1Recruiting

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Role: lead

NCT06206733Phase 3Active Not Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Role: lead

NCT05632939Phase 1Active Not Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Role: lead

NCT05456828Phase 1Active Not Recruiting

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

Role: lead

NCT05940428Phase 1Active Not Recruiting

A Study of ASKG712 in Patients With Diabetic Macular Edema

Role: lead

NCT05509985Phase 1Unknown

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Role: lead

NCT05554666Phase 1Unknown

A Study of ASKG315 in Patients With Advanced Solid Tumors.

Role: lead

All 7 trials loaded